Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 1.00 |
| ▸ | JAK3 | P52333 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 12/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.83 |
| ▸ | SYK | P43405 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ifidancitinib SCHEMBL342002 | 1.00 | JAK1 (1.00) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL29360646 | 1.00 | JAK1 (1.00) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL20767498 | 0.99 | JAK1 (0.98) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL29358204 | 0.96 | JAK1 (0.92) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL29358557 | 0.96 | JAK1 (0.92) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL525194 | 0.96 | JAK1 (0.92) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL525310 | 0.96 | JAK1 (0.92) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL23356291 | 0.95 | JAK1 (0.90) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL23356183 | 0.94 | JAK1 (0.88) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL339570 | 0.94 | JAK1 (0.88) | JAK1JAK3JAK2CYP1A2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114698370-A | Compounds and methods for treating cytokine release syndrome | 里格尔药品股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| EP-4009974-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | claimed |
| US-20220218705-A1 | COMPOUNDS AND METHOD FOR TREATING AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| CN-114698370-A | Compounds and methods for treating cytokine release syndrome | 里格尔药品股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-4009974-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218705-A1 | COMPOUNDS AND METHOD FOR TREATING AUTOIMMUNE DISEASES | NR1H2, CNR2, CNR1 | JAK1 2860/4885JAK3 2785/4885JAK2 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.